Sign up to save your podcasts
Or
Share How to Build and Sell a Biotech in 2024
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
How to Build and Sell a Biotech in 2024
With a combined deal value of $29bn under their belts this year, four CEOs reflect on what they’ve learned from their successes – and failures. Roberto Bellini (who sold BELLUS Health), Mark McKenna (Prometheus), Bill Meury (Karuna Therapeutics) and Dan O’Connor (Ambrx Biopharma) also consider the current market for biopharma M&A and what buyers are seeking today.
View all episodes
By RBC Capital Markets
4.9
1717 ratings
With a combined deal value of $29bn under their belts this year, four CEOs reflect on what they’ve learned from their successes – and failures. Roberto Bellini (who sold BELLUS Health), Mark McKenna (Prometheus), Bill Meury (Karuna Therapeutics) and Dan O’Connor (Ambrx Biopharma) also consider the current market for biopharma M&A and what buyers are seeking today.
More shows like Strategic Alternatives
View all
Exchanges
976 Listeners
Masters in Business
2,168 Listeners
M&A Science
127 Listeners
Capital Allocators – Inside the Institutional Investment Industry
792 Listeners
Wall Street Breakfast
1,030 Listeners
Eye On The Market
289 Listeners
The Bid
257 Listeners
Making Sense
59 Listeners
Thoughts on the Market
1,289 Listeners
At Any Rate
78 Listeners
The Private Equity Podcast, by Raw Selection
32 Listeners
Global Data Pod
26 Listeners
The Markets
75 Listeners
The View From Apollo
25 Listeners
The Credit Edge by Bloomberg Intelligence
26 Listeners